Vertex Pharmaceutic (VRTX)

$469.34 -8.79 (-1.84%)
Market Cap 119.23B
Revenue (ttm) 12.00B
Net Income (ttm) 3.95B
EPS (ttm) N/A
PE Ratio 28.58
Forward PE 28.18
Profit Margin 32.94%
Debt to Equity Ratio 0.00
Volume 1,097,500
Avg Vol 1,501,192
Day's Range N/A - N/A
Shares Out 254.03M
Stochastic %K 33%
Beta 0.31
Analysts Strong Sell
Price Target $545.74

Company Profile

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for peo...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
Yi_YandH
Yi_YandH Mar. 15 at 8:34 PM
$VRTX $ICU MBBB 💃
0 · Reply
Merlintrader
Merlintrader Mar. 15 at 7:48 PM
$VRTX https://www.merlintrader.com/vertex-pharmaceuticals-march15-update/
0 · Reply
svertical1
svertical1 Mar. 13 at 4:22 PM
$VRTX Hasn’t changed! Why $600 near term target is reasonable! Plus Voucher! Some know, but really can’t unsee! CF VS IgAN VS Pain? Big bigger biggest!
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 13 at 2:27 PM
$VRTX this is criminal...
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 9:27 PM
$VRTX take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
Scarlasfly
Scarlasfly Mar. 12 at 8:44 PM
$VRTX This has given back too much. Im going to try and add more.
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Mar. 12 at 4:13 PM
$VRTX most of the bump from their IgA nephropathy drug data almost wiped out here in overall market weakness. Big opp imo on long side. Adding some here 477 and will continue to add now that the data derisked.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 12 at 3:08 PM
$VRTX this thing should be over $500 period, especially after the last P3 news.
0 · Reply
trichomy
trichomy Mar. 12 at 3:52 AM
$INMB $LLY $VRTX $REGN
0 · Reply
trichomy
trichomy Mar. 12 at 2:02 AM
$INMB $LLY $VRTX $REGN 🚀🔥INmuneBio $INMB 🔥🚀
0 · Reply
Latest News on VRTX
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Mar 11, 2026, 2:52 PM EDT - 4 days ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Mar 10, 2026, 1:22 PM EDT - 5 days ago

This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Mar 10, 2026, 1:00 PM EDT - 5 days ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Leerink Global Healthcare Conference 2026 Transcript

Vertex passes key test In quest to treat kidney diseases

Mar 10, 2026, 10:54 AM EDT - 5 days ago

Vertex passes key test In quest to treat kidney diseases

Vertex's kidney disease drug meets main goal in late-stage trial

Mar 9, 2026, 4:13 PM EDT - 6 days ago

Vertex's kidney disease drug meets main goal in late-stage trial

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Mar 9, 2026, 4:02 PM EDT - 6 days ago

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex to Participate in Upcoming March Investor Conferences

Mar 5, 2026, 4:00 PM EST - 10 days ago

Vertex to Participate in Upcoming March Investor Conferences

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Mar 5, 2026, 10:00 AM EST - 10 days ago

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 11:52 AM EST - 12 days ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

Feb 28, 2026, 8:10 AM EST - 15 days ago

10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)

AIO AMGN CVX EIC EOD EOS GAM

Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)

Feb 18, 2026, 1:44 PM EST - 25 days ago

Vertex Pharmaceuticals Stock: Is The Bull Run Over (Rating Downgrade)

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Feb 17, 2026, 4:00 PM EST - 26 days ago

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript

Feb 12, 2026, 10:14 PM EST - 4 weeks ago

Vertex Pharmaceuticals Incorporated (VRTX) Q4 2025 Earnings Call Transcript

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Feb 12, 2026, 4:06 PM EST - 4 weeks ago

Vertex Pharma forecasts 2026 revenue in-line, expects growth in cystic fibrosis treatments

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 12, 2026, 4:01 PM EST - 4 weeks ago

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

Vertex Q4 Earnings Preview: What To Expect This Week

Feb 9, 2026, 11:30 AM EST - 4 weeks ago

Vertex Q4 Earnings Preview: What To Expect This Week

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

Feb 2, 2026, 10:08 PM EST - 5 weeks ago

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-cell Engager

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

Jan 26, 2026, 10:30 PM EST - 6 weeks ago

GreensKeeper Value Fund Q4 2025 Portfolio Update: Long-Term Winners

A ADBE AXP B C CBOE CHKP

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

Jan 22, 2026, 1:19 PM EST - 7 weeks ago

Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil

KMB XOM SPGI

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Jan 20, 2026, 4:00 PM EST - 7 weeks ago

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 11:45 PM EST - 2 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Jan 11, 2026, 5:00 PM EST - 2 months ago

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise

Dec 30, 2025, 11:59 PM EST - 2 months ago

Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Dec 22, 2025, 4:00 PM EST - 2 months ago

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

Best Defensive Stocks To Balance Tech Sector Volatility

Dec 18, 2025, 8:30 AM EST - 3 months ago

Best Defensive Stocks To Balance Tech Sector Volatility

BIP INCY MU RSP XLK

Harbor Capital Appreciation Fund Q3 2025 Portfolio Review

Dec 16, 2025, 4:23 AM EST - 3 months ago

Harbor Capital Appreciation Fund Q3 2025 Portfolio Review

AAPL ABNB AMD AVGO CDNS MSFT NFLX

Vertex's gene therapy shows promise in younger children with blood disorders

Dec 6, 2025, 7:04 AM EST - 3 months ago

Vertex's gene therapy shows promise in younger children with blood disorders

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Dec 6, 2025, 7:01 AM EST - 3 months ago

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 11:33 AM EST - 3 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Nov 19, 2025, 4:00 PM EST - 4 months ago

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

Columbia Contrarian Core Fund Q3 2025 Performance Review

Nov 18, 2025, 6:40 AM EST - 4 months ago

Columbia Contrarian Core Fund Q3 2025 Performance Review

EA EBAY ELV INTU TEL

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

Nov 17, 2025, 4:05 PM EST - 4 months ago

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

INCY PFE PPH XBI XLV

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

Nov 16, 2025, 2:31 PM EST - 4 months ago

PGIM Jennison Health Sciences Fund Q3 2025 Contributors And Detractors

ARGX ARQT ISRG NVO

Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update

Nov 12, 2025, 5:09 AM EST - 4 months ago

Alger Weatherbie Specialized Growth Fund Q3 2025 Portfolio Update

AORT PI PLMR SMTC SPSC

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 2:41 PM EST - 4 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Healthcare Conference 2025 Transcript

Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript

Nov 9, 2025, 1:16 AM EST - 4 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Discusses Updated Data for Pove in IgAN and pMN and Developments in Kidney Disease Portfolio Transcript

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Nov 8, 2025, 5:15 PM EST - 4 months ago

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

Artisan Global Opportunities Fund Q3 2025 Portfolio Update

Nov 6, 2025, 8:10 AM EST - 4 months ago

Artisan Global Opportunities Fund Q3 2025 Portfolio Update

AMZN BSX DKS INSM LHX SPOT TEAM

Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"

Nov 4, 2025, 5:23 PM EST - 4 months ago

Vertex Pharmaceuticals: JOURNAVX Prescription Demand And Povetacicept Developments Warrant "Strong Buy"

Committee stocks on the move: Uber and Vertex Pharma

Nov 4, 2025, 1:22 PM EST - 4 months ago

Committee stocks on the move: Uber and Vertex Pharma

UBER

Columbia Balanced Fund Q3 2025 Portfolio Update

Nov 4, 2025, 2:30 AM EST - 4 months ago

Columbia Balanced Fund Q3 2025 Portfolio Update

EA EBAY ELV INTU TEL

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 10:06 PM EST - 4 months ago

Vertex Pharmaceuticals Incorporated (VRTX) Q3 2025 Earnings Call Transcript

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Nov 3, 2025, 4:20 PM EST - 4 months ago

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

Vertex Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 4 months ago

Vertex Reports Third Quarter 2025 Financial Results

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Nov 3, 2025, 2:23 PM EST - 4 months ago

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings

Oct 28, 2025, 11:59 AM EDT - 4 months ago

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Oct 27, 2025, 4:00 PM EDT - 4 months ago

Vertex to Participate in the UBS Global Healthcare Conference on November 11

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Oct 23, 2025, 9:00 AM EDT - 5 months ago

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Oct 17, 2025, 9:04 AM EDT - 5 months ago

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Oct 6, 2025, 4:00 PM EDT - 5 months ago

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

Yi_YandH
Yi_YandH Mar. 15 at 8:34 PM
$VRTX $ICU MBBB 💃
0 · Reply
Merlintrader
Merlintrader Mar. 15 at 7:48 PM
$VRTX https://www.merlintrader.com/vertex-pharmaceuticals-march15-update/
0 · Reply
svertical1
svertical1 Mar. 13 at 4:22 PM
$VRTX Hasn’t changed! Why $600 near term target is reasonable! Plus Voucher! Some know, but really can’t unsee! CF VS IgAN VS Pain? Big bigger biggest!
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 13 at 2:27 PM
$VRTX this is criminal...
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 9:27 PM
$VRTX take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
Scarlasfly
Scarlasfly Mar. 12 at 8:44 PM
$VRTX This has given back too much. Im going to try and add more.
0 · Reply
THE_Monkey_Banana_Genius
THE_Monkey_Banana_Genius Mar. 12 at 4:13 PM
$VRTX most of the bump from their IgA nephropathy drug data almost wiped out here in overall market weakness. Big opp imo on long side. Adding some here 477 and will continue to add now that the data derisked.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 12 at 3:08 PM
$VRTX this thing should be over $500 period, especially after the last P3 news.
0 · Reply
trichomy
trichomy Mar. 12 at 3:52 AM
$INMB $LLY $VRTX $REGN
0 · Reply
trichomy
trichomy Mar. 12 at 2:02 AM
$INMB $LLY $VRTX $REGN 🚀🔥INmuneBio $INMB 🔥🚀
0 · Reply
trichomy
trichomy Mar. 12 at 1:54 AM
$INMB $LLY $VRTX $REGN 🔥🔥🔥INMB🔥🔥🔥
0 · Reply
abubnic
abubnic Mar. 11 at 9:24 PM
$CRSP down -15% since announcement of convertible notes. Investors are also frustrated over delays in CASGEVY revenue, but $VRTX Execs say "We anticipate this will smooth out in 2027 and beyond as the number of patients at all stages of the treatment journey continues to build.” If you have the time and are a long-term investor, it's a good opportunity to buy the dip. A number of catalysts are still ahead.
2 · Reply
svertical1
svertical1 Mar. 11 at 6:44 PM
$VRTX If you know you know! Either way, you can’t unsee this! FDA Voucher Too!
0 · Reply
BoltTrade
BoltTrade Mar. 11 at 6:07 PM
$SXTP has gone up 55% and still only 2,391 people are watching this stock. Clinical results came in, and all 3 patients were CURED! Let’s talk about 🚀🚀🚀 $VRTX $BNTX $MRNA $CPRX
0 · Reply
Prester_John
Prester_John Mar. 11 at 5:26 PM
$VRTX https://pharmaphorum.com/news/vertex-preps-fda-filing-igan-drug-after-phase-3-readout
1 · Reply
erevnon
erevnon Mar. 11 at 3:49 PM
Truist Securities maintains Vertex Pharmaceuticals $VRTX at Buy and raises the price target from $490 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
Spicy_Trade
Spicy_Trade Mar. 11 at 2:58 PM
SpicyTrade Vertex Pharmaceuticals Incorpor ( $VRTX ) daily stock analysis https://youtu.be/z3v9tRT5t2o?si=soPeuRN2msqWEL6G
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 11 at 2:45 PM
$VRTX how can this be down today?
0 · Reply
Ventureville
Ventureville Mar. 11 at 2:41 PM
Biotech is on fire. $VRTX crushing kidney trials, AI funds pouring $114M into early-stage innovation, and oncology M&A already hitting $2.5B. http://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-week-36-interim-analysis-results Massive tailwind for $BIOV $BVAXF and the DPX platform after positive Phase 1/2 bladder and ovarian cancer data that could reshape immunotherapy.
0 · Reply
svertical1
svertical1 Mar. 11 at 1:58 PM
$VRTX One is not like the other….
0 · Reply
akinyo
akinyo Mar. 11 at 1:18 PM
$VRTX Let’s go to $510!
0 · Reply
t5776
t5776 Mar. 11 at 12:49 PM
$VRTX oops meant for CRSP
0 · Reply